Results 141 to 150 of about 2,752 (194)

Calmodulin Triggers Activity-Dependent rRNA Biogenesis via Interaction with DDX21. [PDF]

J Neurosci
Yang JL, Sun X, Shi JX, Cui QX, Cao XY, Wang KT, An MX, Wu SJ, Yang YL, Sun HZ, Zhao WD.   +10 more
europepmc   +1 more source

Evaluation of comparative efficacy of Umeclidinium/Vilanterol versus other bronchodilators in the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of RCTs. [PDF]

BMC Pulm Med
Zhu H, Lei J, Gao F, Guo Y, Zhao L.
europepmc   +1 more source

Trends in inhaler use and associated carbon footprint: a sales data-based study in Europe. [PDF]

BMJ Open Respir Res
Vartiainen V, Janson C, Hisinger-Mölkänen H, Lehtimäki L, Wilkinson A.   +4 more
europepmc   +1 more source

Exercise and the lungs: From physiology to pathophysiology - a narrative review. [PDF]

Afr J Thorac Crit Care Med
Wills NK, Raine R, Gordon L, van Zyl-Smit RN.   +3 more
europepmc   +1 more source

Inhaled Triple Therapy with Extrafine Single Inhaler Versus Multiple Devices in Chronic Obstructive Pulmonary Disease (TRIPOLI): A Post-Authorization Retrospective Study. [PDF]

Int J Chron Obstruct Pulmon Dis
Cabrera César E, López García J, Vega Lizarazo DE, Benítez-Cano Gamonoso M, Segura Romero M, Sanchez Martín S, León Nieto MI, González-Segura Alsina D, Velasco Garrido JL.   +8 more
europepmc   +1 more source

Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol [PDF]

Respiratory Medicine, 2013
In this randomized, double-blind, crossover study, we explored the acute effects on respiratory function and safety of an additional dose of indacaterol 150 μg in stable COPD patients regularly treated with a conventional dose of indacaterol 150 μg.On two non-consecutive days, patients inhaled indacaterol 150 μg.
Emanuele Stirpe, Paola Rogliani, Josuel Ora   +2 more
exaly   +7 more sources

Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ indacaterol/glycopyrronium in patients with asthma [PDF]

Pulmonary Pharmacology and Therapeutics, 2021
Once-daily (o.d.) fixed-dose combinations of mometasone furoate/indacaterol acetate and mometasone furoate/indacaterol acetate/glycopyrronium bromide, both delivered via the Breezhaler® device, are approved for the maintenance treatment of asthma. Across
Huib Kerstjens, Christian Bartels, Ivan Nikolaev   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Indacaterol

Reactions Weekly, 2012
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Dennis J. Cada, Terri L. Levien, Danial E. Baker   +2 more
  +5 more sources

Safety and tolerability of indacaterol in asthma: A randomized, placebo-controlled 28-day study [PDF]

Respiratory Medicine, 2007
SummaryThe safety and tolerability of indacaterol, a novel once-daily β2-agonist bronchodilator with a fast onset of action, were assessed in 156 asthma patients in a multicentre, randomized, double-blind, placebo-controlled study.
Mark Higgins, Norbert Krug
exaly   +3 more sources

Lipid membrane interactions of indacaterol and salmeterol: Do they influence their pharmacological properties?

European Journal of Pharmaceutical Sciences, 2009
This study compares the lipid membrane interactions of indacaterol, an ultra long acting beta-2 agonist that is given once a day, to salmeterol, a twice a day beta-2 agonist, in order to elucidate the potential mechanisms leading to their different ...
Bernard Cuenoud, Stefanie D Krämer
exaly   +2 more sources